6 results on '"Castelli, Letizia"'
Search Results
2. Additional file 1 of RObotic-Assisted Rehabilitation for balance and gait in Stroke patients (ROAR-S): study protocol for a preliminary randomized controlled trial
- Author
-
Giovannini, Silvia, Iacovelli, Chiara, Brau, Fabrizio, Loreti, Claudia, Fusco, Augusto, Caliandro, Pietro, Biscotti, Lorenzo, Padua, Luca, Bernabei, Roberto, and Castelli, Letizia
- Abstract
Additional file 1. SPIRIT Checklist.
- Published
- 2022
- Full Text
- View/download PDF
3. MSJ765649_STROBE_Checklist – Supplemental material for Balance worsening associated with nabiximols in multiple sclerosis
- Author
-
Castelli, Letizia, Prosperini, Luca, and Pozzilli, Carlo
- Subjects
FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, MSJ765649_STROBE_Checklist for Balance worsening associated with nabiximols in multiple sclerosis by Letizia Castelli, Luca Prosperini and Carlo Pozzilli in Multiple Sclerosis Journal
- Published
- 2018
- Full Text
- View/download PDF
4. MSJ765649_supplementary_tables – Supplemental material for Balance worsening associated with nabiximols in multiple sclerosis
- Author
-
Castelli, Letizia, Prosperini, Luca, and Pozzilli, Carlo
- Subjects
FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, MSJ765649_supplementary_tables for Balance worsening associated with nabiximols in multiple sclerosis by Letizia Castelli, Luca Prosperini and Carlo Pozzilli in Multiple Sclerosis Journal
- Published
- 2018
- Full Text
- View/download PDF
5. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
- Author
-
Domenico Ippolito, Giorgia Teresa Maniscalco, Damiano Paolicelli, Daniele Spitaleri, Francesco Patti, Gianfranco Costantino, Margherita Russo, Clara Grazia Chisari, Letizia Castelli, Giovanna Salamone, Roberto Bruno Bossio, Maria Trotta, Claudio Solaro, Eliana Berra, Roberta Lanzillo, Elisabetta Signoriello, Raffaella Cerqua, Isabella Righini, Fabio Buttari, Gabriella Spinicci, Loredana Petrucci, Angelica Guareschi, Manuela Matta, Mario Zappia, Simona Pontecorvo, Maria Donata Benedetti, Paola Cavalla, Assunta Bianco, Claudio Gasperini, Eleonora Tavazzi, Francesco Saccà, Mauro Zaffaroni, Patti, F., Chisari, C. G., Solaro, C., Benedetti, M. D., Berra, E., Bianco, A., Bruno Bossio, R., Buttari, F., Castelli, L., Cavalla, P., Cerqua, R., Costantino, G., Gasperini, C., Guareschi, A., Ippolito, D., Lanzillo, R., Maniscalco, G. T., Matta, M., Paolicelli, D., Petrucci, L., Pontecorvo, S., Righini, I., Russo, M., Saccà, Francesco, Salamone, G., Signoriello, E., Spinicci, G., Spitaleri, D., Tavazzi, E., Trotta, M., Zaffaroni, M., Zappia, M., Patti, Francesco, Grazia Chisari, Clara, Solaro, Claudio, Donata Benedetti, Maria, Berra, Eliana, Bianco, Assunta, Bruno Bossio, Roberto, Buttari, Fabio, Castelli, Letizia, Cavalla, Paola, Cerqua, Raffaella, Costantino, Gianfranco, Gasperini, Claudio, Guareschi, Angelica, Ippolito, Domenico, Lanzillo, Roberta, Teresa Maniscalco, Giorgia, Matta, Manuela, Paolicelli, Damiano, Petrucci, Loredana, Pontecorvo, Simona, Righini, Isabella, Russo, Margherita, Salamone, Giovanna, Signoriello, Elisabetta, Spinicci, Gabriella, Spitaleri, Daniele, Tavazzi, Eleonora, Trotta, Maria, Zaffaroni, Mauro, and Zappia, Mario
- Subjects
medicine.medical_specialty ,Multiple Sclerosis ,THC ,Neurology ,Dermatology ,Clinical practice ,Spasticity-related symptom ,CBD ,Multiple sclerosis ,Spasticity-related symptoms ,03 medical and health sciences ,0302 clinical medicine ,Rating scale ,Internal medicine ,medicine ,Cannabidiol ,Humans ,Multiple sclerosi ,Dronabinol ,030212 general & internal medicine ,Spasticity ,Oromucosal spray ,Retrospective Studies ,Plant Extracts ,business.industry ,General Medicine ,medicine.disease ,nervous system diseases ,Clinical Practice ,Drug Combinations ,Psychiatry and Mental health ,Italy ,Muscle Spasticity ,Neurology (clinical) ,Neurosurgery ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Introduction: The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice. Materials and methods: MS patients with drug-resistant spasticity were recruited from 30 Italian MS centers. All patients were eligible for THC:CBD treatment according to the approved label: ≥ 18 years of age, at least moderate spasticity (MS spasticity numerical rating scale [NRS] score ≥ 4) and not responding to the common antispastic drugs. Patients were evaluated at baseline (T0) and after 4 weeks of treatment (T1) with the spasticity NRS scale and were also asked about meaningful improvements in 6 key spasticity-related symptoms. Results: Out of 1615 enrolled patients, 1432 reached the end of the first month trial period (T1). Of these, 1010 patients (70.5%) reached a ≥ 20% NRS score reduction compared with baseline (initial responders; IR). We found that 627 (43.8% of 1432) patients showed an improvement in at least one spasticity-related symptom (SRSr group), 543 (86.6%) of them belonging to the IR group and 84 (13.4%) to the spasticity NRS non-responders group. Conclusion: Our study confirmed that the therapeutic benefit of cannabinoids may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients. © 2020, Fondazione Società Italiana di Neurologia.
- Published
- 2020
6. Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study
- Author
-
Damiano Paolicelli, Assunta Bianco, Simona Pontecorvo, Paola Valentino, Elisabetta Capello, Roberta Lanzillo, M. Danni, Alberto Gajofatto, Gianfranco Costantino, Claudio Solaro, Roberto Bruno Bossio, Daniele Spitaleri, Giacomo Lus, Simona Bonavita, Mauro Zaffaroni, Pasquale Annunziata, Edoardo Sessa, Roberto Bergamaschi, Claudio Gasperini, Letizia Castelli, Diego Centonze, Salvatore Cottone, Loredana Petrucci, Vincenzo Brescia Morra, Marco Rovaris, Mario Zappia, Paola Cavalla, Angelica Guareschi, Gabriella Spinicci, Isabella Righini, Francesco Patti, Giorgia Teresa Maniscalco, Manuela Matta, Federica Esposito, Clara Grazia Chisari, Chisari, Clara Grazia, Solaro, Claudio, Annunziata, Pasquale, Bergamaschi, Roberto, Bianco, Assunta, Bonavita, Simona, Brescia Morra, Vincenzo, Bruno Bossio, Roberto, Capello, Elisabetta, Castelli, Letizia, Cavalla, Paola, Costantino, Gianfranco, Centonze, Diego, Cottone, Salvatore, Danni, Maura Chiara, Esposito, Federica, Gajofatto, Alberto, Gasperini, Claudio, Guareschi, Angelica, Lanzillo, Roberta, Lus, Giacomo, Maniscalco, Giorgia Teresa, Matta, Manuela, Paolicelli, Damiano, Petrucci, Loredana, Pontecorvo, Simona, Righini, Isabella, Rovaris, Marco, Sessa, Edoardo, Spinicci, Gabriella, Spitaleri, Daniele, Valentino, Paola, Zaffaroni, Mauro, Zappia, Mario, and Patti, Francesco
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Time Factors ,Nabiximols ,Delta-δ-tetrahydrocannabinol ,cannabidiol: oromucosal spray ,therapy continuation ,therapy abandon ,long-term clinical outcome ,Settore MED/26 ,digestive system ,030226 pharmacology & pharmacy ,Efficacy ,03 medical and health sciences ,Drug withdrawal ,0302 clinical medicine ,Internal medicine ,mental disorders ,Cannabidiol ,Humans ,Medicine ,Dronabinol ,Prospective Studies ,Adverse effect ,Prospective cohort study ,business.industry ,organic chemicals ,Middle Aged ,medicine.disease ,digestive system diseases ,Discontinuation ,Clinical trial ,Drug Combinations ,Psychiatry and Mental health ,Treatment Outcome ,surgical procedures, operative ,Withholding Treatment ,Patient Compliance ,Female ,Surgery ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
IntroductionDelta-δ-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray is used as an add-on therapy option for moderate to severe multiple sclerosis (MS) spasticity resistant to other medications. Aims of this study were to provide real-life data on long-term clinical outcomes in a large population of Italian patients treated with THC:CBD and to evaluate predictors of THC:CBD therapy continuation.Materials and methodsThis prospective observational multicentre Italian study screened all patients with MS consecutively included in the Agenzia Italiana del Farmaco e-registry at the start of THC:CBD treatment (baseline), after 4 weeks (T1), 12±3 weeks (T2), 24±3 weeks (T3), 48±3 weeks (T4) and 72±3 weeks (T5) from baseline.ResultsA total of 1845 patients were recruited from 32 MS Italian centres. At T1, 1502 (81.4%) of patients reached a Numerical Rating Scale (NRS) improvement of ≥20%, with an NRS reduction of 26.9% at T1 and of 34.4% at T5. At T5, 725 patients (48.3% of 1502) discontinued treatment with highest discontinuation rate at T2 and T3. Daily number of puffs was generally stable through the observation period. The multivariate analysis showed that higher NRS scores at baseline (OR 2.28, 95% CI 1.15 to 6.36, pDiscussionTHC:CBD effects were sustained for 18 months with a relatively stable number of puffs per day. About 50% of patients abandoned THC:CBD therapy for loss of efficacy or adverse events.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.